NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









SEED Therapeutics

SEED Therapeutics

Private
King of Prussia, PennsylvaniaHealthcare & Life Scienceshttps://www.seedtherapeutics.com/

Last Round

Series A

Extension

Sep 23, 2025

Est. Valuation

$130M

Total Funding Raised

$80M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

SEED Therapeutics is a biotechnology company that develops targeted protein degradation therapeutics using its proprietary RITE3™ molecular glue platform to treat diseases in oncology, neurodegeneration, and immunology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

molecular glueTPDtargeted protein degradationprotein degraderundruggable proteinsglue degraderbiotechnologydrug discoverysmall-molecule therapeuticsstructure-based drug designcomputational chemistryPROTAC alternativeubiquitin-proteasome systemoncology drug discoveryneurodegeneration therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SEED Therapeutics Comparables

Compare SEED Therapeutics with similar companies based on industry and business-model similarity.

SEED Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Degron Therapeutics
88%
Plexium
88%
Magnet Biomedicine
88%

SEED Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionSep 23, 2025
Series AAug 6, 2024
Series ANov 13, 2020

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 29, 116% of headcount.

  • Aug 14, 2025

    Named a finalist for the 2025 Prix Galien USA 'Best Start-Up' Award.

SEED Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

SEED Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about SEED Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersKing of Prussia, Pennsylvania
Employee Range25
Year Founded2019
Last FundingSep 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.